Two Sigma Advisers LP Buys 158,400 Shares of The Chemours Company (NYSE:CC)

Two Sigma Advisers LP lifted its position in The Chemours Company (NYSE:CC - Free Report) by 31.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 661,500 shares of the specialty chemicals company's stock after acquiring an additional 158,400 shares during the period. Two Sigma Advisers LP owned approximately 0.44% of Chemours worth $11,179,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Barclays PLC lifted its holdings in Chemours by 28.4% during the third quarter. Barclays PLC now owns 107,549 shares of the specialty chemicals company's stock worth $2,185,000 after acquiring an additional 23,766 shares in the last quarter. Inspire Investing LLC raised its position in shares of Chemours by 17.4% during the fourth quarter. Inspire Investing LLC now owns 23,799 shares of the specialty chemicals company's stock worth $402,000 after purchasing an additional 3,523 shares during the period. KBC Group NV lifted its holdings in shares of Chemours by 38.2% during the 4th quarter. KBC Group NV now owns 6,176 shares of the specialty chemicals company's stock valued at $104,000 after purchasing an additional 1,708 shares in the last quarter. Twelve Points Wealth Management LLC grew its position in shares of Chemours by 42.8% in the 4th quarter. Twelve Points Wealth Management LLC now owns 78,325 shares of the specialty chemicals company's stock valued at $1,324,000 after purchasing an additional 23,490 shares during the period. Finally, EMC Capital Management increased its stake in Chemours by 74.6% during the 4th quarter. EMC Capital Management now owns 9,534 shares of the specialty chemicals company's stock worth $161,000 after purchasing an additional 4,073 shares in the last quarter. Institutional investors own 76.26% of the company's stock.

Chemours Stock Up 2.4%

CC traded up $0.25 on Tuesday, hitting $10.55. 2,227,763 shares of the company were exchanged, compared to its average volume of 2,092,602. The stock's fifty day moving average is $11.88 and its 200-day moving average is $15.89. The Chemours Company has a 12 month low of $9.33 and a 12 month high of $26.98. The company has a debt-to-equity ratio of 6.70, a quick ratio of 0.92 and a current ratio of 1.68. The company has a market cap of $1.58 billion, a PE ratio of 18.50 and a beta of 1.76.

Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.06). Chemours had a return on equity of 26.54% and a net margin of 1.51%. The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.36 billion. During the same period last year, the firm earned $0.32 EPS. The firm's revenue for the quarter was up .4% compared to the same quarter last year. Equities research analysts predict that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Announces Dividend

The company also recently announced a dividend, which will be paid on Monday, June 16th. Investors of record on Monday, May 19th will be issued a dividend of $0.0875 per share. The ex-dividend date is Friday, May 16th. This represents a yield of 3.17%. Chemours's payout ratio is 175.00%.

Insiders Place Their Bets

In other Chemours news, CFO Shane Hostetter purchased 4,450 shares of the stock in a transaction on Monday, May 19th. The shares were purchased at an average price of $11.28 per share, with a total value of $50,196.00. Following the completion of the transaction, the chief financial officer now directly owns 59,694 shares in the company, valued at $673,348.32. This represents a 8.06% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.47% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on CC. Truist Financial reduced their price target on shares of Chemours from $27.00 to $22.00 and set a "buy" rating for the company in a report on Monday, April 14th. Mizuho set a $15.00 price target on Chemours in a research note on Tuesday, April 15th. UBS Group cut their price target on Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. The Goldman Sachs Group decreased their price objective on Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a report on Wednesday, May 14th. Finally, Wall Street Zen cut Chemours from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $17.56.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.